v3.26.3
Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Nov. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Company formation date   2007-03 2007-03 2007-03 2007-03 2007-03  
Accumulated deficit   $ (551,538)   $ (551,538)   $ (545,646) $ (486,039)
Common stock value      
Prepaid advance principal amount $ 7,500            
Prepaid advance transaction price 7,150            
Cash and cash equivalents   1,544   1,544   7,118 49,046
Impairment losses           0 0
Pre Paid Advance in Fair Value           7,150  
Accrued clinical trial cost           5,800  
Money Market Funds [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Cash and cash equivalents           $ 4,300 $ 38,800
Standby Equity Purchase Agreement [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Common stock value $ 15,000 15,000 $ 15,000 15,000 $ 15,000    
Proceeds from sale common of stock   $ 400   $ 400      
Standby Equity Purchase Agreement [Member] | Liquidity And Going Concern [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Number of shares sold under transaction   48,092   48,092